Suspended

Beta-Carotene and Macular Degeneration Prevention Study

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Data Collection

Who is being recruted

Eye Diseases+1

+ Macular Degeneration

+ Retinal Degeneration

From 40 to 84 Years
See all eligibility criteria
How is the trial designed

Prevention Study

Phase 3
Interventional
Study Start: April 1982
See protocol details

Summary

Principal SponsorNational Eye Institute (NEI)
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: April 1, 1982

Actual date on which the first participant was enrolled.

Macular degeneration is a leading cause of blindness, especially in people aged 65 and older in the United States. This condition affects over 100,000 people each year, with no known prevention methods or treatments for most patients. The cause of macular degeneration remains unclear, but research suggests that antioxidants like beta-carotene might play a protective role. This study is part of the Physicians Health Study, sponsored by the National Heart, Lung, and Blood Institute, and focuses on exploring the potential of beta-carotene in preventing macular degeneration. The trial involves over 22,000 physicians who are randomly assigned to take either beta-carotene or a placebo. In this trial, participants take one 50-mg beta-carotene capsule every other day. The study measures the effectiveness of beta-carotene by comparing the occurrence of macular degeneration between the group taking beta-carotene and the group taking a placebo. Any reported diagnoses of macular degeneration are confirmed through medical record reviews. The Cox proportional hazards model is used to determine whether there is a difference in time to diagnosis of macular degeneration between the two groups. This study aims to shed light on the potential protective role of beta-carotene in preventing macular degeneration and to identify any additional risk factors.

Official TitleRandomized Trial of Beta-Carotene and Macular Degeneration
Principal SponsorNational Eye Institute (NEI)
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Prevention Study

Prevention studies aim to stop a disease from developing. They often involve people at risk and test things like vaccines, lifestyle changes, or preventive medications.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Male

Biological sex of participants that are eligible to enroll.

From 40 to 84 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Eye DiseasesMacular DegenerationRetinal DegenerationRetinal Diseases

Criteria

When the Physicians Health Study was established in the early 1980s by the NHLBI to collect data on a stable population at risk for heart attack, only male physicians were studied because males were thought to be at higher risk than females for ischemic heart problems. The study population consists of 22,071 male U.S. physicians who were aged 40 to 84 years in 1982. The subjects have no history of myocardial infarction, cancer, kidney disease, renal disease, or any other contraindication to the use of aspirin or beta-carotene, including regular use of corticosteroids.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.
This study has no location dataSave this study to your profile to know when the location data is available.
SuspendedNo study centers